{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,15]],"date-time":"2026-01-15T00:36:04Z","timestamp":1768437364797,"version":"3.49.0"},"reference-count":27,"publisher":"FapUNIFESP (SciELO)","issue":"7","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Rev. Assoc. Med. Bras."],"published-print":{"date-parts":[[2017,7]]},"abstract":"<jats:p>Summary Objective: To characterize the frequency of HER-2-positive breast cancer in Brazil. Method: In this prospective observational study, we first ascertained the HER-2 status of invasive breast cancer specimens by automated immunohistochemistry (IHC). For specimens classified as 2+ by IHC, we performed in situ hybridization (ISH). Results: From February, 2011 to December, 2012, 1,495 breast specimens were registered, and 1,310 samples collected at 24 centers were analyzed. Median patient age was 54 years, and the majority of samples were obtained from segmental (46.9%) or radical mastectomy (34.4%). The predominant histological type was invasive breast carcinoma of no special type (85%), 64.3% had tubule formation (grade 3), and estrogen\/progesterone receptors (ER\/PR) were positive in 77.4\/67.8% of the specimens analyzed, respectively. Using IHC, we found a negative HER-2 status (0 or 1+) in 72.2% of specimens, and 3+ in 18.5%; the 9.3% scored as 2+ were further analyzed by ISH, of which 15.7% were positive (thus, 20.0% of samples were HER-2- -positive by either method). We found no association between HER-2 scores and menopausal status or histological type. Tumors classified as 3+ came from younger patients, and had higher histological grade and less frequent expression of ER\/PR. In the North region of Brazil, 34.7% of samples were 3+, with lower frequencies in the other four regions of the country. Conclusion: Our findings provide estimates for the frequency of HER-2 positivity in Brazil and raise the hypothesis that biological differences may underlie the different distribution of breast-cancer phenotypes among different Brazilian regions.<\/jats:p>","DOI":"10.1590\/1806-9282.63.07.566","type":"journal-article","created":{"date-parts":[[2017,9,30]],"date-time":"2017-09-30T23:28:42Z","timestamp":1506814122000},"page":"566-574","source":"Crossref","is-referenced-by-count":4,"title":["Assessment of HER-2 status in invasive breast cancer in Brazil"],"prefix":"10.1590","volume":"63","author":[{"given":"Victor Eduardo Arrua","family":"Arias","sequence":"first","affiliation":[{"name":"Hospital P\u00e9rola Byington, Brazil"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Helenice","family":"Gobbi","sequence":"additional","affiliation":[{"name":"Universidade Federal de Minas Gerais, Brazil"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S\u00e9rgio Ossamu","family":"Ioshii","sequence":"additional","affiliation":[{"name":"Hospital Erasto Gaertner, Brazil"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cristovam","family":"Scapulatempo","sequence":"additional","affiliation":[{"name":"Hospital de C\u00e2ncer de Barretos, Brazil"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alexandre Rolim da","family":"Paz","sequence":"additional","affiliation":[{"name":"Universidade Federal da Para\u00edba, Brazil"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vinicius Duval da","family":"Silva","sequence":"additional","affiliation":[{"name":"Pontif\u00edcia Universidade Cat\u00f3lica do Rio Grande do Sul, Brazil"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Diego","family":"Uch\u00f4a","sequence":"additional","affiliation":[{"name":"Hospital de Cl\u00ednicas de Porto Alegre, Brazil"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Claudio","family":"Zettler","sequence":"additional","affiliation":[{"name":"Irmandade da Santa Casa de Porto Alegre, Brazil"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fernando Augusto","family":"Soares","sequence":"additional","affiliation":[{"name":"A.C. Camargo Cancer Center, Brazil"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"530","reference":[{"issue":"1","key":"ref1","doi-asserted-by":"crossref","first-page":"52","DOI":"10.3322\/caac.21203","article-title":"Breast cancer statistics, 2013","volume":"64","author":"DeSantis C","year":"2014","journal-title":"CA Cancer J Clin"},{"key":"ref2","series-title":"GLOBOCAN 2012: Estimated Cancer Incidence, Mortality and Prevalence Worldwide in 2012"},{"key":"ref3","series-title":"Estimativa 2014: Incid\u00eancia de c\u00e2ncer no Brasil"},{"issue":"8","key":"ref4","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1056\/NEJMra0801289","article-title":"Gene-expression signatures in breast cancer","volume":"360","author":"Sotiriou C","year":"2009","journal-title":"N Engl J Med"},{"issue":"19","key":"ref5","doi-asserted-by":"crossref","first-page":"2078","DOI":"10.1200\/JCO.2013.54.0948","article-title":"Systemic therapy for patients with advanced human epidermal growth factor receptor 2-positive breast cancer: American Society of Clinical Oncology clinical practice guideline","volume":"32","author":"Giordano SH","year":"2014","journal-title":"J Clin Oncol"},{"issue":"16","key":"ref6","doi-asserted-by":"crossref","first-page":"1972","DOI":"10.1001\/jama.291.16.1972","article-title":"HER-2 testing in breast cancer using parallel tissue-based methods","volume":"291","author":"Yaziji H","year":"2004","journal-title":"JAMA"},{"issue":"31","key":"ref7","doi-asserted-by":"crossref","first-page":"3997","DOI":"10.1200\/JCO.2013.50.9984","article-title":"Recommendations for human epidermal growth factor receptor 2 testing in breast cancer American Society of Clinical Oncology\/College of American Pathologists clinical practice guideline update","volume":"31","author":"Wolff AC","year":"2013","journal-title":"J Clin Oncol"},{"issue":"4785","key":"ref8","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1126\/science.3798106","article-title":"Human breast cancer correlation of relapse and survival with amplification of the HER-2\/neu oncogene","volume":"235","author":"Slamon DJ","year":"1987","journal-title":"Science"},{"issue":"11","key":"ref9","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1056\/NEJM200103153441101","article-title":"Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2","volume":"344","author":"Slamon DJ","year":"2001","journal-title":"N Engl J Med"},{"issue":"19","key":"ref10","doi-asserted-by":"crossref","first-page":"1783","DOI":"10.1056\/NEJMoa1209124","article-title":"Trastuzumab emtansine for HER2-positive advanced breast cancer","volume":"367","author":"Verma S","year":"2012","journal-title":"N Engl J Med"},{"issue":"8","key":"ref11","doi-asserted-by":"crossref","first-page":"724","DOI":"10.1056\/NEJMoa1413513","article-title":"Pertuzumab, trastuzumab, and docetaxel in HER2-positive metastatic breast cancer","volume":"372","author":"Swain SM","year":"2015","journal-title":"N Engl J Med"},{"issue":"8","key":"ref12","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1056\/NEJMoa053028","article-title":"Adjuvant docetaxel or vinorelbine with or without trastuzumab for breast cancer","volume":"354","author":"Joensuu H","year":"2006","journal-title":"N Engl J Med"},{"issue":"16","key":"ref13","doi-asserted-by":"crossref","first-page":"1673","DOI":"10.1056\/NEJMoa052122","article-title":"Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer","volume":"353","author":"Romond EH","year":"2005","journal-title":"N Engl J Med"},{"issue":"9555","key":"ref14","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/S0140-6736(07)60028-2","article-title":"2-year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: a randomised controlled trial","volume":"369","author":"Smith I","year":"2007","journal-title":"Lancet"},{"issue":"3","key":"ref15","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1016\/j.humpath.2004.11.010","article-title":"Assessment of the HER2 status in breast cancer by fluorescence in situ hybridization: a technical review with interpretive guidelines","volume":"36","author":"Hicks DG","year":"2005","journal-title":"Hum Pathol"},{"key":"ref16","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1186\/1472-6874-14-102","article-title":"Geographic differences in the distribution of molecular subtypes of breast cancer in Brazil","volume":"14","author":"Carvalho FM","year":"2014","journal-title":"BMC Womens Health"},{"key":"ref17","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1186\/1472-6874-14-110","article-title":"Molecular breast cancer subtypes and therapies in a public hospital of northeastern Brazil","volume":"14","author":"de Macedo Andrade AC","year":"2014","journal-title":"BMC Womens Health"},{"issue":"10","key":"ref18","doi-asserted-by":"crossref","first-page":"1489","DOI":"10.1097\/PAS.0b013e3182635987","article-title":"Evaluation of reliability of FISH versus brightfield dual-probe in situ hybridization (BDISH) for frontline assessment of HER2 status in breast cancer samples in a community setting influence of poor tissue preservation","volume":"36","author":"Schiavon BN","year":"2012","journal-title":"Am J Surg Pathol"},{"issue":"5","key":"ref19","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1111\/j.1365-2559.1991.tb00229.x","article-title":"Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long-term follow-up","volume":"19","author":"Elston CW","year":"1991","journal-title":"Histopathology"},{"issue":"1","key":"ref20","doi-asserted-by":"crossref","first-page":"18","DOI":"10.5858\/2007-131-18-ASOCCO","article-title":"American Society of Clinical Oncology\/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer","volume":"131","author":"Wolff AC","year":"2007","journal-title":"Arch Pathol Lab Med"},{"issue":"3","key":"ref21","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1002\/path.1370","article-title":"Expression of the HER1-4 family of receptor tyrosine kinases in breast cancer","volume":"200","author":"Witton CJ","year":"2003","journal-title":"J Pathol"},{"key":"ref22","series-title":"Censo","year":"2010"},{"issue":"6","key":"ref23","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1097\/PAS.0b013e3181d96231","article-title":"Silver in situ hybridization (SISH) for determination of HER2 gene status in breast carcinoma comparison with FISH and assessment of interobserver reproducibility","volume":"34","author":"Papouchado BG","year":"2010","journal-title":"Am J Surg Pathol"},{"issue":"2","key":"ref24","doi-asserted-by":"crossref","first-page":"153","DOI":"10.3816\/CBC.2006.n.025","article-title":"Concordance between central and local laboratory HER2 testing from a community-based clinical study","volume":"7","author":"Reddy JC","year":"2006","journal-title":"Clin Breast Cancer"},{"issue":"11","key":"ref25","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1093\/jnci\/94.11.855","article-title":"Concordance between local and central laboratory HER2 testing in the breast intergroup trial N9831","volume":"94","author":"Roche PC","year":"2002","journal-title":"J Natl Cancer Inst"},{"issue":"2","key":"ref26","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1097\/PAI.0b013e3181f0b044","article-title":"HER2 testing in breast carcinoma: very low concordance rate between reference and local laboratories in Brazil","volume":"19","author":"Wludarski SC","year":"2011","journal-title":"Appl Immunohistochem Mol Morphol"},{"issue":"5","key":"ref27","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1309\/AJCP99WZGBPKCXOQ","article-title":"Effect of ischemic time, fixation time, and fixative type on HER2\/neu immunohistochemical and fluorescence in situ hybridization results in breast cancer","volume":"136","author":"Moatamed NA","year":"2011","journal-title":"Am J Clin Pathol"}],"container-title":["Revista da Associa\u00e7\u00e3o M\u00e9dica Brasileira"],"original-title":[],"link":[{"URL":"http:\/\/www.scielo.br\/pdf\/ramb\/v63n7\/0104-4230-ramb-63-07-0566.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,8,3]],"date-time":"2022-08-03T20:37:41Z","timestamp":1659559061000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.scielo.br\/scielo.php?script=sci_arttext&pid=S0104-42302017000700566&lng=en&tlng=en"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,7]]},"references-count":27,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2017,7]]}},"alternative-id":["S0104-42302017000700566"],"URL":"https:\/\/doi.org\/10.1590\/1806-9282.63.07.566","relation":{},"ISSN":["0104-4230"],"issn-type":[{"value":"0104-4230","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,7]]}}}